<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01102491</url>
  </required_header>
  <id_info>
    <org_study_id>B-1001/091-003</org_study_id>
    <nct_id>NCT01102491</nct_id>
  </id_info>
  <brief_title>Additional Anti-emetic Effect of Ramosetron Prophylaxis After Total Knee Arthroplasty</brief_title>
  <official_title>The Effect of Multimodal Anti-emetic Protocol on Postoperative Nausea and Vomiting After Total Knee Arthroplasty</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purposes of this study are to document the antiemetic efficacy of multimodal antiemetic
      protocol in patient after Total Knee Arthroplasty using regional anesthesia, midazolam &amp;
      propofol, hydration &amp; oxygen supplement, preemptive &amp; multimodal contemporary pain management
      and to determine whether Ramosetron prophylaxis would provide additional antiemetic effect on
      this protocol. We hypothesized that the incidence of Postoperative nausea and vomiting during
      multimodal antiemetic protocol would be lower than Apfel's expected postoperative nausea and
      vomiting incidence. It was also hypothesized that Ramosetron prophylaxis would provide
      additional antiemetic effect.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Immediate postoperative pain after Total Knee Arthroplasty(TKA) remains an unsolved problem,
      and a substantial proportion of patients experience moderate to severe postoperative pain.
      Patient controlled analgesia(PCA) using opioid is an effective and safe modality for
      postoperative pain relief after TKA and remains an integral part of pain management after
      TKA. However, Opioid is associated with high incidence of postoperative nausea and
      vomiting(PONV) which is the most frequent complication during the first 24 hour after
      surgery.PONV has been reported to be more distressing than postoperative pain and to be the
      most undesirable negative outcome. Despite advances in prevention and treatment of PONV, PONV
      remains a continuing problem with an incidence of 20-30% in unselected patients and up to 70%
      in &quot;high-risk&quot; patients. As results of current researches, some risk factors of PONV have
      been identified and indications of prophylactic antiemetics and strategies to reduce baseline
      risk have been recommended.The recommended modalities to reduce baseline risk includes
      regional anesthesia, oxygen supplement, use of midazolam and propofol and avoid use of
      inhaled anesthesia and neuromuscular blockade. In addition,published evidence suggests that
      appropriate antiemetic prophylaxis should be considered for patients with 2 or more risk
      factors and to reduce opioid consumption, preemptive multimodal pain management such as
      preemptive analgesic medication, continuous regional nerve block is recommended.Ramosetron is
      a newly developed serotonin receptor antagonist with a higher affinity and longer duration of
      action than that of the previously developed serotonin receptor antagonist such as
      ondansetron and granisetron. Thus, this prospective blinded randomized study was conducted to
      document the antiemetic efficacy of multimodal antiemetic protocol to reduce baseline risk,
      using regional anesthesia, midazolam and propofol, hydration and oxygen supplement and
      multimodal pain control protocols using the continuous femoral nerve block, PCA and
      preemptive oral medications and to determine whether Ramosetron prophylaxis would provide
      additional antiemetic effect in patients after TKA for whom covered by this multimodal
      antiemetic protocols.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2009</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">February 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Nausea and Vomiting</measure>
    <time_frame>within 48 hours after surgery</time_frame>
    <description>outcomes assessor who is blinded to randomization assessed the incidence of postoperative nausea which was defined as subjectively unpleasant sensation associated with awareness of the urge to vomit and an emetic episode and vomiting</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Rescue Antiemetic Administration</measure>
    <time_frame>within 48 hours after surgery</time_frame>
    <description>outcome assessor assessed the incidence of rescue antiemetic administration</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">153</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Ramosetron prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>no antiemetic prophylaxis</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ramosetron</intervention_name>
    <description>ramosetron intravenous injection, 0.3mg, 1 time/day for 2 days</description>
    <arm_group_label>Ramosetron prophylaxis</arm_group_label>
    <other_name>Nasea</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosis of primary osteoarthritis, knee

          -  Scheduled for elective total knee arthroplasty

          -  Signed written informed consent

        Exclusion Criteria:

          -  Refusing participate

          -  Contraindication to regional anesthesia

          -  Severe impairment of bowel motility

          -  administration of other antiemetics within 24hours before surgery

          -  systemic steroid within 24hours before surgery

          -  history of cardiovascular &amp; respiratory disease

          -  renal &amp; hepatic failure
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>86 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>T K Kim, MD,PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Joint Recontruction Center, Seoul National University Bundang hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Joint Reconstruction Center, Seoul National University Bundang Hospital</name>
      <address>
        <city>Seongnam-si</city>
        <state>Gyeonggi-do</state>
        <zip>463-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 8, 2010</study_first_submitted>
  <study_first_submitted_qc>April 9, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 13, 2010</study_first_posted>
  <results_first_submitted>April 26, 2010</results_first_submitted>
  <results_first_submitted_qc>April 26, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">May 21, 2010</results_first_posted>
  <last_update_submitted>June 3, 2012</last_update_submitted>
  <last_update_submitted_qc>June 3, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>postoperative nausea and vomiting</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
    <mesh_term>Postoperative Nausea and Vomiting</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ramosetron</mesh_term>
    <mesh_term>Antiemetics</mesh_term>
    <mesh_term>Emetics</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>153 patients whose diagnosis was primary osteoarthritis scheduled for unilateral total knee arthroplasty(TKA)at Seoul National University Bundang Hospital from October 2009 to March 2010 were recruited.</recruitment_details>
      <pre_assignment_details>11 patients were excluded before assignment. 6 were other diagnosis such as rheumatoid arthritis, secondary osteoarthritis, 2 were refused to participate this study, and 3 were serious medical conditions such as respiratory failure, heart failure.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Ramosetron Prophylaxis</title>
          <description>ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery</description>
        </group>
        <group group_id="P2">
          <title>Control</title>
          <description>no antiemetic prophylaxis</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="71"/>
                <participants group_id="P2" count="71"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="60">11 patient excluded</participants>
                <participants group_id="P2" count="59">12 patients were excluded</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Protocol Violation</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="12"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ramosetron Prophylaxis</title>
          <description>ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery</description>
        </group>
        <group group_id="B2">
          <title>Control</title>
          <description>no antiemetic prophylaxis</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="71"/>
            <count group_id="B2" value="71"/>
            <count group_id="B3" value="142"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="58"/>
                    <measurement group_id="B2" value="55"/>
                    <measurement group_id="B3" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="69.1" spread="6.3"/>
                    <measurement group_id="B2" value="69.0" spread="7.5"/>
                    <measurement group_id="B3" value="69.1" spread="6.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="64"/>
                    <measurement group_id="B2" value="65"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="71"/>
                    <measurement group_id="B3" value="142"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Incidence of Nausea and Vomiting</title>
        <description>outcomes assessor who is blinded to randomization assessed the incidence of postoperative nausea which was defined as subjectively unpleasant sensation associated with awareness of the urge to vomit and an emetic episode and vomiting</description>
        <time_frame>within 48 hours after surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ramosetron Prophylaxis</title>
            <description>ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery</description>
          </group>
          <group group_id="O2">
            <title>Control</title>
            <description>no antiemetic prophylaxis</description>
          </group>
        </group_list>
        <measure>
          <title>Incidence of Nausea and Vomiting</title>
          <description>outcomes assessor who is blinded to randomization assessed the incidence of postoperative nausea which was defined as subjectively unpleasant sensation associated with awareness of the urge to vomit and an emetic episode and vomiting</description>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="71"/>
                <count group_id="O2" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                    <measurement group_id="O2" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.05</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Incidence of Rescue Antiemetic Administration</title>
        <description>outcome assessor assessed the incidence of rescue antiemetic administration</description>
        <time_frame>within 48 hours after surgery</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Ramosetron Prophylaxis</title>
          <description>ramosetron prophylaxis at the end of surgery with starting PCA and 1 day after surgery</description>
        </group>
        <group group_id="E2">
          <title>Control</title>
          <description>no antiemetic prophylaxis</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Drowsiness</sub_title>
                <counts group_id="E1" subjects_affected="27" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="25" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>headache</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="71"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>TK Kim</name_or_title>
      <organization>Joint Reconstruction Center, Seoul National University Bundang Hospital</organization>
      <phone>82-31-787-7196</phone>
      <email>osktk@snubh.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

